They found that among women with a history of migraine, use of Wegovy for weight management was linked to a 7% reduction in the use of triptan-class drugs for treatment in migraine one year after they started weight-loss treatment. The authors said that after women started Wegovy, the use of migraine medicines started to gradually decrease.
But the finding was only observed among women. The authors concluded: “The study suggests that initiation of semaglutide is associated with a gradual reduction in triptan use during the first year after initiation among women.”
